Major Investor Catalyst4 Increases Stake to 47.9% in MapLight Therapeutics
MPLT sits 41% above its 52-week low of $9.1.
Summary
Catalyst4, Inc. has significantly boosted its ownership in MapLight Therapeutics to 47.9% through a $15.3 million stock purchase, signaling high confidence in the company.
Key Events · Ownership and Investor Activity · MPLT
-
Increased Ownership
Catalyst4, Inc. and its affiliates now beneficially own 20,906,689 shares, representing 47.9% of MapLight Therapeutics' common stock.
-
Significant Investment
The reporting persons acquired an additional 1,209,225 shares for approximately $15.3 million in open market transactions between July 28-30, 2026.
-
Amended Disclosure
This Schedule 13D/A updates a previous filing, noting a material increase in ownership percentage. The purchases were previously disclosed in a Form 4 on July 30, 2026.
Analysis · MPLT · Life Sciences
Catalyst4, Inc., a significant investor, has materially increased its beneficial ownership in MapLight Therapeutics through recent open market purchases totaling $15.3 million. This amendment to their Schedule 13D reveals their stake has grown to 47.9% of the company's common stock, indicating strong conviction in the company's prospects. This follows recent positive Phase 2 trial results for ML-007C-MA in schizophrenia.
At the time of this filing, MPLT was trading at $12.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $534.9M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.